scholarly article | Q13442814 |
P50 | author | Joseph Sodroski | Q64524473 |
P2093 | author name string | L Huang | |
A B Pardee | |||
W Hofmann | |||
I Bosch | |||
P2860 | cites work | HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor | Q22242268 |
Identification of a major co-receptor for primary isolates of HIV-1 | Q22251282 | ||
The Tat protein of human immunodeficiency virus type 1, a growth factor for AIDS Kaposi sarcoma and cytokine-activated vascular cells, induces adhesion of the same cell types by using integrin receptors recognizing the RGD amino acid sequence | Q24561727 | ||
Human immunodeficiency virus type 1 Tat upregulates interleukin-2 secretion in activated T cells | Q24649124 | ||
The expression of the interleukin 6 gene is induced by the human immunodeficiency virus 1 TAT protein | Q24680024 | ||
Tat protein induces self-perpetuating permissivity for productive HIV-1 infection | Q24683211 | ||
A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors | Q28118386 | ||
HIV-1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix-associated heparan sulfate proteoglycans through its basic region | Q28252310 | ||
HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease | Q28267375 | ||
The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates | Q28282895 | ||
HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure | Q28283258 | ||
HIV-1-Tat protein promotes chemotaxis and invasive behavior by monocytes | Q28286968 | ||
Exogenous human immunodeficiency virus type-1 Tat protein selectively stimulates a phosphatidylinositol-specific phospholipase C nuclear pathway in the Jurkat T cell line | Q28291464 | ||
CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1 | Q28646859 | ||
Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene | Q29614892 | ||
Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS | Q59057787 | ||
What can stochastic resonance do? | Q59061953 | ||
Immune Hyperactivation of HIV-1-Infected T Cells Mediated by Tat and the CD28 Pathway | Q63351477 | ||
Pleiotropic effects of immobilized versus soluble recombinant HIV-1 Tat protein on CD3-mediated activation, induction of apoptosis, and HIV-1 long terminal repeat transactivation in purified CD4+ T lymphocytes | Q71396779 | ||
Lipopolysaccharide (LPS) down-regulates CD4 expression in primary human macrophages through induction of endogenous tumour necrosis factor (TNF) and IL-1β | Q71808694 | ||
Evidence for the differential expression of the functional alpha-melanocyte-stimulating hormone receptor MC-1 on human monocytes | Q73271324 | ||
Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection | Q29614956 | ||
HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5 | Q29616094 | ||
Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. | Q29622903 | ||
CCR5 expression correlates with susceptibility of maturing monocytes to human immunodeficiency virus type 1 infection | Q33782193 | ||
Bioassay for trans-activation using purified human immunodeficiency virus tat-encoded protein: trans-activation requires mRNA synthesis | Q33834125 | ||
HIV-1 replication is controlled at the level of T cell activation and proviral integration | Q33919765 | ||
Reciprocal modulations between p53 and Tat of human immunodeficiency virus type 1 | Q34226294 | ||
The role of CCR5 and CCR2 polymorphisms in HIV-1 transmission and disease progression | Q34442744 | ||
A seven-transmembrane domain receptor involved in fusion and entry of T-cell-tropic human immunodeficiency virus type 1 strains. | Q35868457 | ||
CXCR4 expression during lymphopoiesis: implications for human immunodeficiency virus type 1 infection of the thymus | Q35892412 | ||
Endocytosis and targeting of exogenous HIV-1 Tat protein | Q35926764 | ||
The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes | Q36028490 | ||
Identification of an Arg-Gly-Asp (RGD) cell adhesion site in human immunodeficiency virus type 1 transactivation protein, tat | Q36223757 | ||
CD4 down-regulation by nef alleles isolated from human immunodeficiency virus type 1-infected individuals | Q36363328 | ||
Chemoattractants attract HIV researchers | Q36367072 | ||
Interleukin-2 regulates CC chemokine receptor expression and chemotactic responsiveness in T lymphocytes. | Q36367109 | ||
Bacterial lipopolysaccharide rapidly inhibits expression of C-C chemokine receptors in human monocytes | Q36376839 | ||
CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1, in vitro | Q36377185 | ||
Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation | Q36639380 | ||
Vpu-induced degradation of CD4: requirement for specific amino acid residues in the cytoplasmic domain of CD4. | Q36655137 | ||
Effects of the human immunodeficiency virus type 1 Tat protein on the expression of inflammatory cytokines | Q36687077 | ||
Rapid complementation assays measuring replicative potential of human immunodeficiency virus type 1 envelope glycoprotein mutants | Q36806278 | ||
Differential regulation of HIV-1 fusion cofactor expression by CD28 costimulation of CD4+ T cells | Q38933102 | ||
Co-receptors for HIV-1 entry | Q39265878 | ||
Macrophage-tropic HIV: critical for AIDS pathogenesis? | Q39273394 | ||
Utilization of chemokine receptors, orphan receptors, and herpesvirus-encoded receptors by diverse human and simian immunodeficiency viruses | Q39413069 | ||
Macrophage tropism: fact or fiction? | Q39489497 | ||
Viral latency in HIV disease. | Q40456335 | ||
Tat and the HIV-1 promoter | Q40835492 | ||
An autocrine loop of HIV type-1 Tat protein responsible for the improved survival/proliferation capacity of permanently Tat-transfected cells and required for optimal HIV-1 LTR transactivating activity | Q41278999 | ||
Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp120. | Q41335848 | ||
Induction of apoptosis in uninfected lymphocytes by HIV-1 Tat protein | Q41349382 | ||
Interleukin 10 increases CCR5 expression and HIV infection in human monocytes | Q41779916 | ||
The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. | Q43521980 | ||
HIV-1 envelope glycoprotein gp120 down-regulates CD4 expression in primary human macrophages through induction of endogenous tumour necrosis factor-alpha | Q44030691 | ||
Modulation of surface antigens of a human monocyte cell line, U937, during incubation with T lymphocyte-conditioned medium: detection of T4 antigen and its presence on normal blood monocytes | Q44145033 | ||
Loss of circulating T4+ monocytes in patients infected with HTLV-III. | Q44248235 | ||
HIV-1-Tat modulates the function of monocytes and alters their interactions with microvessel endothelial cells. A mechanism of HIV pathogenesis | Q44498807 | ||
Evidence that T cell activation is required for HIV-1 entry in CD4+ lymphocytes. | Q44968448 | ||
The human immunodeficiency virus type-1 Tat protein upregulates Bcl-2 gene expression in Jurkat T-cell lines and primary peripheral blood mononuclear cells | Q45788521 | ||
Activation of monocytes by HIV-Tat treatment is mediated by cytokine expression. | Q52192468 | ||
Genetic Restriction of HIV-1 Infection and Progression to AIDS by a Deletion Allele of the CKR5 Structural Gene | Q56591978 | ||
P433 | issue | 11 | |
P921 | main subject | Human T-lymphotropic virus 1 | Q1280388 |
P1104 | number of pages | 9 | |
P304 | page(s) | 8952-8960 | |
P577 | publication date | 1998-11-01 | |
P1433 | published in | Journal of Virology | Q1251128 |
P1476 | title | Tat protein induces human immunodeficiency virus type 1 (HIV-1) coreceptors and promotes infection with both macrophage-tropic and T-lymphotropic HIV-1 strains | |
P478 | volume | 72 |
Q35874415 | A monoclonal antibody directed against a conformational epitope of the HIV-1 trans-activator (Tat) protein neutralizes cross-clade |
Q35785031 | A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rhe |
Q40156071 | A role for mitogen-activated protein kinase and Ets-1 in the induction of interleukin-10 transcription by human immunodeficiency virus-1 Tat. |
Q24794033 | Anti-HIV-1 activity of anionic polymers: a comparative study of candidate microbicides |
Q92906228 | Anti-Tat Immunity in HIV-1 Infection: Effects of Naturally Occurring and Vaccine-Induced Antibodies Against Tat on the Course of the Disease |
Q44111908 | Blocking HIV replication by targeting Tat protein |
Q36438574 | CXC and CC chemokine receptors on coronary and brain endothelia |
Q34129756 | Chemokines and their receptors in infectious disease |
Q35198110 | Chemokines and viruses: friends or foes? |
Q36961218 | Comparative study of Tat vaccine regimens in Mauritian cynomolgus and Indian rhesus macaques: influence of Mauritian MHC haplotypes on susceptibility/resistance to SHIV(89.6P) infection |
Q37347813 | Contribution of nonneutralizing vaccine-elicited antibody activities to improved protective efficacy in rhesus macaques immunized with Tat/Env compared with multigenic vaccines. |
Q59511395 | Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine |
Q33786297 | Differential effects of HIV type 1 clade B and clade C Tat protein on expression of proinflammatory and antiinflammatory cytokines by primary monocytes |
Q40676905 | Exosome-associated release, uptake, and neurotoxicity of HIV-1 Tat protein. |
Q34425378 | Extracellular HIV Tat and Tat cysteine rich peptide increase CCR5 expression in monocytes |
Q37033190 | Follicular dendritic cells and human immunodeficiency virus type 1 transcription in CD4+ T cells |
Q34033148 | From the outside in: extracellular activities of HIV Tat. |
Q36520900 | HIV Tat controls RNA Polymerase II and the epigenetic landscape to transcriptionally reprogram target immune cells |
Q35552889 | HIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant blood HIV DNA: results of a randomized phase II exploratory clinical trial |
Q34556390 | HIV-1 Tat vaccines |
Q90221085 | HIV-1 Tat: Role in Bystander Toxicity |
Q33581852 | HIV-1 clade B Tat, but not clade C Tat, increases X4 HIV-1 entry into resting but not activated CD4+ T cells |
Q34477471 | HIV-1 tat promotes integrin-mediated HIV transmission to dendritic cells by binding Env spikes and competes neutralization by anti-HIV antibodies |
Q33671675 | HIV-1-based defective lentiviral vectors efficiently transduce human monocytes-derived macrophages and suppress replication of wild-type HIV-1 |
Q36986644 | HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4(+) T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trial |
Q33825196 | Human anti-HIV-1 tat sFv intrabodies for gene therapy of advanced HIV-1-infection and AIDS. |
Q24564662 | Human immunodeficiency virus type 1 Tat increases the expression of cleavage and polyadenylation specificity factor 73-kilodalton subunit modulating cellular and viral expression |
Q40565403 | Human immunodeficiency virus type 1 Tat protein modulates cell cycle and apoptosis in Epstein-Barr virus-immortalized B cells |
Q34234127 | Human immunodeficiency virus type-1 and chemokines: beyond competition for common cellular receptors |
Q34792498 | Human retroviruses after 20 years: a perspective from the past and prospects for their future control |
Q52541976 | Immunization with a novel HIV-1-Tat multiple-peptide conjugate induces effective immune response in mice. |
Q33908773 | Induction of neutralizing antibodies and Th1-polarized and CD4-independent CD8+ T-cell responses following delivery of human immunodeficiency virus type 1 Tat protein by recombinant adenylate cyclase of Bordetella pertussis |
Q21245111 | Interaction of human dipeptidyl peptidase IV and human immunodeficiency virus type-1 transcription transactivator in Sf9 cells |
Q51998598 | Long-term protection against SHIV89.6P replication in HIV-1 Tat vaccinated cynomolgus monkeys. |
Q28211059 | Macrophage inflammatory protein-1 |
Q45742451 | Minimization of chronic plasma viremia in rhesus macaques immunized with synthetic HIV-1 Tat peptides and infected with a chimeric simian/human immunodeficiency virus (SHIV33). |
Q37509718 | Molecular and genetic characterization of natural HIV-1 Tat Exon-1 variants from North India and their functional implications |
Q35020357 | Monocytes treated with human immunodeficiency virus Tat kill uninfected CD4(+) cells by a tumor necrosis factor-related apoptosis-induced ligand-mediated mechanism. |
Q45722188 | Mucosal delivery of the human immunodeficiency virus-1 Tat protein in mice elicits systemic neutralizing antibodies, cytotoxic T lymphocytes and mucosal IgA. |
Q39683362 | Outcome of simian-human immunodeficiency virus strain 89.6p challenge following vaccination of rhesus macaques with human immunodeficiency virus Tat protein |
Q40508633 | Phosphatidylinositol-(4,5)-bisphosphate enables efficient secretion of HIV-1 Tat by infected T-cells |
Q58853523 | Prediction of human-Bacillus anthracis protein–protein interactions using multi-layer neural network |
Q24799564 | Proliferative activity of extracellular HIV-1 Tat protein in human epithelial cells: expression profile of pathogenetically relevant genes |
Q33769035 | Regulation of HIV-1 transcription |
Q43000456 | Replication of HIV-1 viruses in the presence of the Portland alpha1-antitrypsin variant (alpha1-PDX) inhibitor |
Q37519397 | Role of Tat protein in HIV neuropathogenesis |
Q24673389 | Selective CXCR4 antagonism by Tat: implications for in vivo expansion of coreceptor use by HIV-1 |
Q39023036 | Selective up-regulation of functional CXCR4 expression in erythroid cells by HIV-1 Tat protein |
Q40273841 | Sequence variation within the dominant amino terminus epitope affects antibody binding and neutralization of human immunodeficiency virus type 1 Tat protein |
Q77914240 | Structure and function of HIV-1 and SIV Tat proteins based on carboxy-terminal truncations, chimeric Tat constructs, and NMR modeling |
Q37605089 | Suppressor of cytokine signaling 3 inhibits antiviral IFN-beta signaling to enhance HIV-1 replication in macrophages |
Q42273481 | T-Cell Signaling in HIV-1 Infection |
Q35993736 | Tat as one key to HIV-induced immune pathogenesis and Tat (correction of Pat) toxoid as an important component of a vaccine |
Q39130522 | Tat is a multifunctional viral protein that modulates cellular gene expression and functions |
Q24524076 | Tat protein of human immunodeficiency virus type 1 induces interleukin-10 in human peripheral blood monocytes: implication of protein kinase C-dependent pathway |
Q34755910 | Tat-neutralizing antibodies in vaccinated macaques |
Q34218503 | The Tat protein of human immunodeficiency virus-1 enhances hepatitis C virus replication through interferon gamma-inducible protein-10. |
Q34460375 | The basis for HIV immunotherapeutic vaccines |
Q81571700 | The binding affinity of double-stranded RNA motifs to HIV-1 Tat protein affects transactivation and the neutralizing capacity of anti-Tat antibodies elicited after intranasal immunization |
Q42175449 | The deleterious influence of tenofovir-based therapies on the progression of atherosclerosis in HIV-infected patients |
Q33320187 | The landscape of human proteins interacting with viruses and other pathogens |
Q26823236 | The macrophage: a therapeutic target in HIV-1 infection |
Q38273151 | The two sides of Tat. |
Q28476094 | Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAART |
Q22010658 | Trafficking of the HIV coreceptor CXCR4. Role of arrestins and identification of residues in the c-terminal tail that mediate receptor internalization |
Q35024694 | Transactivation and signaling functions of Tat are not correlated: biological and immunological characterization of HIV-1 subtype-C Tat protein |
Q48382561 | Two B cell epitopes of HIV-1 Tat protein have limited antigenic polymorphism in geographically diverse HIV-1 strains |
Q45012988 | Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P). |
Q35114827 | Vaccination with tat toxoid attenuates disease in simian/HIV-challenged macaques |
Q33933260 | Viral exploitation and subversion of the immune system through chemokine mimicry |
Q26780313 | Virological Mechanisms in the Coinfection between HIV and HCV |